论文部分内容阅读
目的探讨恶性血液病患者外周血细胞ＤＮＡ含量的变化在诊治中的意义。方法采用ＦＣＭ检测１１１例患者外周血单个核细胞的ＤＮＡ含量并进行分析比较。结果（１）恶性血液病组处于增殖期的Ｓ、Ｇ２／Ｍ期细胞ＤＮＡ含量明显高于恶性肿瘤组及非恶性肿瘤组，而Ｇ０／Ｇ１期细胞的ＤＮＡ含量相对低于后两组，Ｐ均＜０．０１。（２）初发组及复发组患者Ｓ、Ｇ２／Ｍ期细胞ＤＮＡ含量及ＰＩ明显高于正常对照组和缓解组，Ｐ＜０．０５或＜０．０１。（３）不同病种间Ｓ期ＤＮＡ含量及ＰＩＣＬ＞ＡＬ＞ＮＨＬ，但前两组间比较Ｐ＞０．０５，前两组与后一组比较Ｐ分别＜０．０１和＜０．０５。结论ＦＣＭ检测外周血细胞ＤＮＡ含量既能反映患者血细胞的增殖状况，也能随时进行动态监测，指导治疗。
Objective To investigate the significance of changes in DNA content in peripheral blood cells of patients with hematologic malignancies during diagnosis and treatment. Methods The DNA content of peripheral blood mononuclear cells in 111 patients was detected by FCM and analyzed. Results (1) The DNA content of S, G2/M phase cells in the proliferative phase of malignant hematologic disease group was significantly higher than that of malignant tumor group and non-malignant tumor group, while the DNA content of G0/G1 phase cells was relatively lower than that of the latter two groups. Both <0.01. (2) The DNA content and PI of S and G2/M phase cells in the primary and recurrent patients were significantly higher than those in the normal and remission groups, P<0.05 or <0.01. (3) DNA content in S phase and PICL>AL>NHL in different disease groups, but P>0.05 in the former two groups, P<0.01 and <0.05 in the former two groups and the latter group, respectively. Conclusion FCM detection of peripheral blood cell DNA content can reflect the proliferation of blood cells in patients, but also can be dynamically monitored at any time to guide treatment.